Biomarker Assay as Alternative to Early-Stage Prostate Cancer Detection

Jake Micallef, PhD
Published: Thursday, May 12, 2016



Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

In the retrospective study, researchers collected blood samples of 537 men—half of whom had prostate cancer. The NuQ test is described as 93% cancer-specific, Micallef explains, adding that this is a higher specificity than prostate-specific antigen (PSA) screening.

Additionally, the test was found to detect more than 70% of early-stage prostate cancers and 86% of late-stage disease.



Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

In the retrospective study, researchers collected blood samples of 537 men—half of whom had prostate cancer. The NuQ test is described as 93% cancer-specific, Micallef explains, adding that this is a higher specificity than prostate-specific antigen (PSA) screening.

Additionally, the test was found to detect more than 70% of early-stage prostate cancers and 86% of late-stage disease.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x